COMP <GO>
SXTP vs CMND // EV/EBITDA & P/E VALUATION
60 Degrees Pharmaceuticals Inc. (NASDAQ) VS. Clearmind Medicine Inc. (NASDAQ) • 15-METRIC TALLY: SXTP 2
— CMND 0
■ METRIC PARITY
LAST: $0.95 (+11.87%) • MKT CAP: $3.3M
valuation
—
LAST: $5.85 (-3.46%) • MKT CAP: $3.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SXTP VS. CMND)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SXTP | CMND | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 22.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 65.50% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.6 | 43.2 | +5.43 | SXTP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.3M | $3.0M | $364.0K | SXTP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SXTP REV | CMND REV | SXTP GROSS % | CMND GROSS % | SXTP FCF | CMND FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.0M | — | 22.3% | — | -$7.0M | — |
| FY 2024 | $607.6K | — | 36.7% | — | -$5.8M | — |
| FY 2023 | $253.6K | — | — | — | -$4.5M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SXTP // BETA —
CMND // BETA —